This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ertürk, E. Articles by Bryan, G. T. Search for Related Content PubMed PubMed Citation Articles by Ertürk, E. Articles by Bryan, G. T.

Induction, Histogenesis, and Isotransplantability of Renal Tumors Induced by Formic Acid 2-[4-(5-Nitro-2-furyl)-2-thiazolyl]-hydrazide in Rats¹

Division of Clinical Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53706

Formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide induced a high incidence of renal tumors arising in the epithelium of the proximal convoluted tubules in Sprague-Dawley male and female and Buffalo female rats. To ascertain the malignant potential of these renal tubular tumors, formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl] hydrazide-induced neoplasms, including cortical (tubular) adenomas, low-grade renal tubular carcinomas, and highly malignant renal tubular carcinomas (adenocarcinomas), were transplanted s.c. to weanling female Sprague-Dawley rats. Chemically induced, small, histologically benign, cortical adenomas demonstrated the same characteristics of cancer as renal tubular carcinomas after 3 serial transplantations. All histologically different tumor lines had the same latent periods, rapid growth rates, and identical histological features with high mitotic activity and extreme cellular pleomorphism when compared with the solid cellular tubular carcinomas. Thus, benign-appearing renal tubular adenomas induced by formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide possess many attributes of cancer and may indeed be regarded as carcinomas.

¹ Supported in part by Grant CA-10017 and Contract PH 43-66-888 from the National Cancer Institute and by a grant from the Wisconsin Division of the American Cancer Society.

² Medical Scientist Trainee of the National Institute of General Medical Sciences (GM-01932).

³ Career Development Awardee of the National Cancer Institute (1-K4-CA-8245).

Received 9/19/69. Accepted 4/ 8/70.